DateTitle 
December 17, 2014POZEN’s YOSPRALA™ Receives Complete Response Letter from The FDAPrinter Friendly Version
December 01, 2014POZEN Inc. and Sanofi US Mutually Agree to Terminate U.S. Partnership for PA8140/PA32540Printer Friendly Version
November 06, 2014POZEN Reports Third Quarter 2014 ResultsPrinter Friendly Version
October 30, 2014POZEN Announces November 6th Webcast of Third Quarter 2014 ResultsPrinter Friendly Version
October 23, 2014POZEN Announces Receipt of Three Patents from the United States Patent and Trademark OfficePrinter Friendly Version
August 20, 2014POZEN Announces U.S. Rights For TREXIMET® Have Been Acquired by Pernix TherapeuticsPrinter Friendly Version
August 07, 2014POZEN Reports Second Quarter 2014 ResultsPrinter Friendly Version
July 24, 2014POZEN Announces August 7th Webcast of Second Quarter 2014 ResultsPrinter Friendly Version
July 16, 2014POZEN Announces FDA Acceptance of Refiling of New Drug Application for PA8140/PA32540 TabletsPrinter Friendly Version
July 01, 2014POZEN Resubmits PA8140/PA32540 NDAPrinter Friendly Version
May 14, 2014POZEN Announces U.S. Rights for Treximet® to Be Acquired by Pernix TherapeuticsPrinter Friendly Version
May 08, 2014POZEN Reports First Quarter 2014 ResultsPrinter Friendly Version
May 01, 2014POZEN Announces May 8th Webcast of First Quarter 2014 ResultsPrinter Friendly Version
April 25, 2014POZEN’S PA8140/PA32540 Receives a Complete Response Letter From FDA Citing Issues at a Facility of a Third Party Supplier of an Active IngredientPrinter Friendly Version
April 02, 2014Pozen Submits Final Study Report for PA8140/PA32540 Phase 1 Study on SchedulePrinter Friendly Version
March 05, 2014POZEN Reports Fourth Quarter & Year End 2013 ResultsPrinter Friendly Version
March 04, 2014POZEN to Present at the Roth Capital Partners 26th Annual Growth Stock ConferencePrinter Friendly Version
February 26, 2014POZEN Announces March 5th Webcast of Fourth Quarter and Year End 2013 ResultsPrinter Friendly Version
January 02, 2014POZEN Announces Appointment of Dennis McNamara to Senior Vice President and Chief Business OfficerPrinter Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.